Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Réglementation et droit · 05/10/20161 min de lecture
Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers
Traduction automatique locale · Langue originale de la source
Résumé
The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Kite Pharma, Inc. ("Kite") located in Santa Monica, CA to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →